Full CoverageEli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
By Emily Mullin
Top news
Lilly expects orforglipron obesity results in third quarter
By Deena Beasley
Lilly’s Experimental Obesity Pill Holds Up to Scrutiny in Trial
By Madison Muller
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
All coverage
Orforglipron Lowers A1c, Weight in Early Type 2 Diabetes
By Miriam E. Tucker
Lilly’s amylin candidate shows early promise
By Meghana Keshavan
Lilly's oral GLP-1 achieves up to 1.6% A1C reduction and 16 lb weight loss in late-stage diabetes trial
By Brian Buntz
Eli Lilly posts trial data for oral obesity drug (LLY:NYSE)
By Dulan Lokuwithana
Lilly Notches ‘Top-Tier’ Weight Loss Results for Phase I Amylin/Tirzepatide Combo
By Annalee Armstrong
Lilly posts encouraging early-stage weight loss data on amylin candidate
By Elizabeth Cairns
Lilly’s Experimental Obesity Drug Shows Promise in Early Study
By Madison Muller
Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
By Dulan Lokuwithana
Experimental obesity drug shows promise
By Madison Muller